Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Prima BioMed Releases Interim Immune Monitoring Data From CVac Clinical Trial
Interim Immune Monitoring Data Demonstrate Positive Effects of CVac(TM); Conference Call to Present the Data Scheduled for November 15th

SYDNEY, AUSTRALIA -- (Marketwire) -- 11/13/12 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") today released interim immune monitoring data from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy.

The interim data demonstrate the positive effects of CVac treatment on the immune system.

The Company has completed intracellular cytokine staining ("ICS") analysis of seven patients from the CAN-003 trial -- five patients from the CVac group and two patients from the control group, who did not receive any cancer treatment during the study.

As compared to the control group, the CVac patients demonstrated much higher T cell activity throughout the testing period. ICS testing also indicates that the T cell response is specific to mucin 1, the antigen marker present on most ovarian cancer cells.

Prof. Ian Frazer, the chairman of Prima's scientific advisory board commented: "There is clear evidence of a cellular response to mucin 1 induced by CVac treatment. We look forward to further analysis of all patients on the CAN-003 study to see if these early trends are confirmed."

Matthew Lehman, Prima's CEO, stated: "We are encouraged by the interim trends we have seen in the CAN-003 data released to date. CVac has a very favourable side effect profile, the clinical data in terms of progression free survival are trending in the right direction, and the early ICS data support our hypothesis of how the product should work in a patient's body."

ICS is a laboratory technique used to evaluate if CVac has induced a desired mucin 1 specific T cell response in patients treated with CVac. The ICS results help confirm the biological activity of CVac.

Prima will make a presentation of the CAN-003 interim data via a conference call and webcast on Thursday November 15th at 9:00am (Sydney local time).

Conference call and webcast details:

Conference call dial-in numbers:


Australia Toll Free                1 800 131 617
Australia Alternate Toll Free      1 800 838 758
Canada/USA                         1 855 237 2970
Germany                            0800 189 9369

Webcast Link:

The webcast can be accessed via the following link;
http://services.choruscall.com/links/primabiomed121113.html

Before launching the webcast, it is recommended to click on the link and then on "Test your systems configuration." A replay of the teleconference and webcast will be available through Prima's website following the live event.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

About CAN-003
CAN-003 is an open label, randomized, multinational, controlled phase 2 study. Sixty-three ovarian cancer patients in first or second remission have been enrolled. The first seven patients were not randomized and all received CVac. Subsequently, 29 patients were randomized to the CVac group compared to 27 patients in the observation standard of care group.

For further information please contact:
Australia Investor/Media
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
MapDB is an Apache-licensed open source database specifically designed for Java developers. The library uses the standard Java Collections API, making it totally natural for Java developers to use and adopt, while scaling database size from GBs to TBs. MapDB is very fast and supports a...
Dell and Red Hat Inc. have announced the availability of co-engineered, enterprise-grade, private cloud solutions based on OpenStack, the Dell Red Hat Cloud Solution, powered by Red Hat Enterprise Linux OpenStack Platform. The companies also have extended their collaboration to enable...
Last week was a crazy week for information security. That's probably also the understatement of the year. With the public exposure of Heartbleed, everyone was talking about what to do and how to do it to help customers and the Internet, in general, deal with the ramifications of such a...
Jelastic on Tuesday announced support for multiple ISV software packages in Jelastic’s products for enterprises, hosting service providers and developers. This support is achieved using OpenShift by Red Hat’s pluggable Cartridge standard, allowing those developers to build application ...
Red Hat on Monday announced OpenShift Marketplace, a one-stop shop that will enable customers to find and try solutions for their cloud applications. The OpenShift Marketplace will bring the power of Red Hat's OpenShift Platform-as-a-Service (PaaS) partner ecosystem directly to OpenShi...
ActiveState on Monday announced that Bernard Golden has joined the company as Vice President of Strategy. Named in Wired.com as one of the ten most influential people in cloud computing, Bernard has extensive experience working with organizations to help them adopt and integrate cloud ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE